Agile Therapeutics, Inc.
AGRXNASDAQHealthcare
$1.51
+$0.05(+3.42%)
Market Cap$10425795
P/E Ratio—
52W High$2.63
52W Low$0.2
Agile Therapeutics, Inc. (AGRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AGRX · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 12, 2024EPS Actual
-$0.68
Revenue
$0.01B
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 12, 2024
After Market Close
AGRX reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2025 | Aug 11, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 13, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 26, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 7, 2024 | — | — | — | — | — | — |
| — Q3 FY2024 | Aug 12, 2024 | — | -$0.68 | — | $0.01B | — | — |
| ▼ Q2 FY2024 | May 15, 2024 | -$0.51 | -$0.63 | -23.5% | $0.01B | $0.00B | +52.4% |
| ▼ Q1 FY2024 | Mar 28, 2024 | -$0.92 | -$1.46 | -58.7% | $0.00B | $0.00B | -11.2% |
| ▲ Q4 FY2023 | Nov 9, 2023 | -$1.84 | -$1.47 | +20.1% | $0.01B | $0.01B | -27.6% |
Q3 FY2025
Aug 11, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 26, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 7, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 12, 2024
EPS Actual
-$0.68
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q2 FY2024
May 15, 2024Miss
EPS Actual
-$0.63
EPS Est.
-$0.51
EPS Surpr.
-23.5%
Revenue
$0.01B
Q1 FY2024
Mar 28, 2024Miss
EPS Actual
-$1.46
EPS Est.
-$0.92
EPS Surpr.
-58.7%
Revenue
$0.00B
Q4 FY2023
Nov 9, 2023Beat
EPS Actual
-$1.47
EPS Est.
-$1.84
EPS Surpr.
+20.1%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2024 | $0.10 | $0.10 | $0.10 | 1 |
| Q3 FY2024 | $-0.04 | $-0.04 | $-0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2024 | Aug 12, 2024 | — | $1.46 | $1.46 | +0.34% |
| ▼ Q2 FY2024 | May 15, 2024 | -23.5% | $0.38 | $0.38 | +0.47% |
| ▼ Q1 FY2024 | Mar 28, 2024 | -58.7% | $0.37 | $0.34 | -8.11% |
| ▲ Q4 FY2023 | Nov 9, 2023 | +20.1% | $1.98 | $2.05 | +3.54% |
| ▲ Q3 FY2023 | Aug 9, 2023 | +10.9% | $2.59 | $2.30 | -11.20% |
| ▼ Q2 FY2023 | May 11, 2023 | -3.5% | $5.85 | $5.68 | -2.91% |
| ▲ Q1 FY2023 | Mar 22, 2023 | +14.3% | $12.05 | $13.35 | +10.79% |
| ▲ Q4 FY2022 | Nov 7, 2022 | +23.3% | $13.35 | $15.95 | +19.48% |
Q3 FY2024+0.34%
Report Date
Aug 12, 2024
EPS Beat/Miss
—
Price Before
$1.46
Price After
$1.46
Q2 FY2024+0.47%
Report Date
May 15, 2024
EPS Beat/Miss
-23.5%
Price Before
$0.38
Price After
$0.38
Q1 FY2024-8.11%
Report Date
Mar 28, 2024
EPS Beat/Miss
-58.7%
Price Before
$0.37
Price After
$0.34
Q4 FY2023+3.54%
Report Date
Nov 9, 2023
EPS Beat/Miss
+20.1%
Price Before
$1.98
Price After
$2.05
Q3 FY2023-11.20%
Report Date
Aug 9, 2023
EPS Beat/Miss
+10.9%
Price Before
$2.59
Price After
$2.30
Q2 FY2023-2.91%
Report Date
May 11, 2023
EPS Beat/Miss
-3.5%
Price Before
$5.85
Price After
$5.68
Q1 FY2023+10.79%
Report Date
Mar 22, 2023
EPS Beat/Miss
+14.3%
Price Before
$12.05
Price After
$13.35
Q4 FY2022+19.48%
Report Date
Nov 7, 2022
EPS Beat/Miss
+23.3%
Price Before
$13.35
Price After
$15.95
Avg Beat Reaction+5.65%
Avg Miss Reaction-3.52%
Beat Rate4 / 8 quarters
Largest Move+19.48% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AGRX ends December
Agile Therapeutics, Inc. (AGRX) most recently reported earnings on August 12, 2024 for Q3 FY2024, posting EPS of $-0.68 (in line with the analyst consensus of —). The next AGRX earnings date is expected around September 1, 2026.
Each quarter, investors track AGRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AGRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AGRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AGRX earnings · 4 questionsAgile Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. AGRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AGRX historically reports after market close (AMC).
AGRX earnings datewhen is AGRX earningsAGRX next earnings datewhen does AGRX report earningsAGRX earnings calendar
▸ Source: FMP · Agile Therapeutics, Inc. SEC filings · US GAAP · Agile Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026